ContextVision Past Earnings Performance
Past criteria checks 3/6
ContextVision has been growing earnings at an average annual rate of 28.3%, while the Healthcare Services industry saw earnings growing at 6.7% annually. Revenues have been growing at an average rate of 8.1% per year. ContextVision's return on equity is 42.1%, and it has net margins of 24.7%.
Key information
28.3%
Earnings growth rate
28.3%
EPS growth rate
| Healthcare Services Industry Growth | 2.9% |
| Revenue growth rate | 8.1% |
| Return on equity | 42.1% |
| Net Margin | 24.7% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Mar 11
ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear
Feb 22ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 18Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)
Jan 26When Should You Buy ContextVision AB (publ) (OB:CONTX)?
Jun 22Is There Now An Opportunity In ContextVision AB (publ) (OB:CONTX)?
Jun 16Why ContextVision AB (publ) (OB:CONTX) Could Be Worth Watching
Mar 08Do ContextVision's (OB:CONTX) Earnings Warrant Your Attention?
Apr 19ContextVision AB (publ)'s (OB:CONTX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 13Here's What ContextVision AB (publ)'s (OB:CONTX) Shareholder Ownership Structure Looks Like
Feb 14
ContextVision (OB:CONTX) Shareholders Have Enjoyed A Whopping 664% Share Price Gain
Jan 19Are ContextVision's (OB:CONTX) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Dec 24Are Robust Financials Driving The Recent Rally In ContextVision AB (publ)'s (OB:COV) Stock?
Nov 28Revenue & Expenses BreakdownBeta
How ContextVision makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 133 | 33 | 28 | 0 |
| 30 Sep 23 | 135 | 37 | 31 | 0 |
| 30 Jun 23 | 130 | 36 | 28 | 0 |
| 31 Mar 23 | 128 | 36 | 27 | 0 |
| 31 Dec 22 | 123 | 33 | 26 | 0 |
| 30 Sep 22 | 117 | 34 | 18 | 0 |
| 30 Jun 22 | 115 | 37 | 16 | 0 |
| 31 Mar 22 | 106 | 35 | 13 | 0 |
| 31 Dec 21 | 100 | 35 | 10 | 0 |
| 30 Sep 21 | 94 | 53 | 4 | 0 |
| 30 Jun 21 | 90 | 42 | 6 | 0 |
| 31 Mar 21 | 86 | 35 | 8 | 0 |
| 31 Dec 20 | 95 | 38 | 10 | 0 |
| 30 Sep 20 | 99 | 8 | 19 | 0 |
| 30 Jun 20 | 100 | 10 | 20 | 0 |
| 31 Mar 20 | 103 | 13 | 20 | 0 |
| 31 Dec 19 | 95 | 7 | 21 | 0 |
| 30 Sep 19 | 95 | 14 | 23 | 0 |
| 30 Jun 19 | 94 | 11 | 25 | 0 |
| 31 Mar 19 | 93 | 5 | 30 | 0 |
| 31 Dec 18 | 91 | -1 | 33 | 0 |
| 30 Sep 18 | 85 | -2 | 32 | 0 |
| 30 Jun 18 | 82 | -3 | 30 | 0 |
| 31 Mar 18 | 82 | -2 | 29 | 0 |
| 31 Dec 17 | 81 | -2 | 28 | 0 |
| 30 Sep 17 | 83 | -1 | 28 | 0 |
| 30 Jun 17 | 85 | 1 | 28 | 0 |
| 31 Mar 17 | 81 | 0 | 26 | 0 |
| 31 Dec 16 | 82 | 4 | 23 | 0 |
| 30 Sep 16 | 76 | 3 | 21 | 0 |
| 30 Jun 16 | 73 | 4 | 19 | 0 |
| 31 Mar 16 | 72 | 5 | 18 | 0 |
| 31 Dec 15 | 72 | 5 | 18 | 0 |
| 30 Sep 15 | 70 | 5 | 17 | 0 |
| 30 Jun 15 | 67 | 4 | 18 | 0 |
| 31 Mar 15 | 65 | 5 | 18 | 0 |
| 31 Dec 14 | 64 | 5 | 19 | 0 |
| 30 Sep 14 | 64 | 8 | 19 | 0 |
| 30 Jun 14 | 65 | 9 | 18 | 0 |
| 31 Mar 14 | 63 | 5 | 19 | 0 |
| 31 Dec 13 | 61 | 5 | 19 | 0 |
| 30 Sep 13 | 66 | 4 | 20 | 0 |
| 30 Jun 13 | 66 | 3 | 20 | 0 |
Quality Earnings: CONTX has high quality earnings.
Growing Profit Margin: CONTX's current net profit margins (24.7%) are lower than last year (27%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CONTX has become profitable over the past 5 years, growing earnings by 28.3% per year.
Accelerating Growth: CONTX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CONTX had negative earnings growth (-1.8%) over the past year, making it difficult to compare to the Healthcare Services industry average (8.6%).
Return on Equity
High ROE: CONTX's Return on Equity (42.1%) is considered outstanding.